Tesamorelin: The FDA-Approved GHRH Analog With Clinical Evidence for Visceral Fat Reduction

What Is Tesamorelin?

Tesamorelin is a synthetic peptide GHRH analog and the only compound in this class with a current FDA approval. It has Phase III clinical trial data demonstrating visceral fat reduction, and emerging research suggesting cognitive benefits.

Tesamorelin (marketed as Egrifta and Egrifta SV by Theratechnologies) is a modified form of human GHRH(1-44) with a trans-3-hexenoic acid group at the N-terminus. This modification improves enzymatic stability compared to native GHRH, though the half-life (~26 minutes) still requires daily injection.

The FDA approved tesamorelin in 2010 for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, a metabolic complication of antiretroviral therapy that causes pathological visceral fat accumulation. While this is a specific indication, the underlying mechanism (GH-mediated lipolysis) is not unique to HIV lipodystrophy, which has driven interest in tesamorelin for broader applications in visceral fat reduction and age-related metabolic decline.

For context on how tesamorelin fits among other GHRH analogs, see also sermorelin (formerly FDA-approved, extensive safety record) and CJC-1295 (longer-acting but without FDA approval).

Who this page is for, and who it isn’t for

This page is for readers who want to understand tesamorelin’s clinical evidence, mechanism, and where it stands relative to other GHRH analogs. It is written for researchers, clinicians, and informed readers evaluating the available data.

This page is not a prescribing guide or a substitute for medical consultation. Tesamorelin is a prescription medication. Its FDA-approved use is specific to HIV-associated lipodystrophy. Off-label use should be managed by a qualified practitioner.

How Tesamorelin Works

Tesamorelin activates the GHRH receptor to stimulate endogenous GH release, with the resulting GH elevation driving lipolysis, particularly in visceral adipose tissue.

GHRH receptor agonism

Like sermorelin and CJC-1295, tesamorelin binds to the GHRH receptor on pituitary somatotroph cells, stimulating endogenous GH synthesis and release. The downstream effects include:

• Lipolysis in adipose tissue, particularly visceral (deep abdominal) fat
• IGF-1 elevation, mediating some of GH’s downstream metabolic effects
• Lean mass preservation (GH has protein-sparing effects)

Why visceral fat responds preferentially

The most clinically significant finding with tesamorelin is its preferential effect on visceral adipose tissue (VAT), the metabolically active deep abdominal fat associated with insulin resistance, cardiovascular disease, and systemic inflammation.

Visceral adipocytes have a higher density of both GH receptors and beta-adrenergic receptors compared to subcutaneous fat cells. This receptor distribution means GH-driven lipolysis is disproportionately active in visceral fat, a selectivity that is relevant for metabolic health, since visceral fat is more strongly associated with cardiometabolic risk than subcutaneous fat.

In clinical trials, tesamorelin reduced visceral fat by approximately 15-18% as measured by CT scan, without significantly affecting subcutaneous fat or lean mass.

Emerging cognitive connection

An unexpected research direction: preliminary data suggests tesamorelin may have cognitive benefits. The GH/IGF-1 axis is known to support neuroplasticity, neuronal survival, and possibly amyloid clearance. While the mechanism is not fully understood, the findings are generating interest beyond the metabolic space.

What the Clinical Evidence Shows

Tesamorelin has more rigorous clinical trial data than any other GHRH analog for body composition outcomes. The following summarizes the key evidence.

Phase III trials for HIV-associated lipodystrophy

Two pivotal Phase III trials (combined n=816) evaluated tesamorelin in HIV-positive patients with excess visceral fat:

• Trunk fat reduction: approximately 18% decrease in visceral fat vs. placebo, measured by CT scan
• IGF-1 normalization: tesamorelin increased IGF-1 levels into the normal range
• Lipid improvements: modest improvements in triglycerides and total cholesterol
• Lean mass: slight increase in lean body mass
• Tolerability: no significant safety concerns beyond injection site reactions

(Falutz et al., 2007)

These results are notable because visceral fat was measured by CT, a precise, objective method that is more reliable than scales or circumference measurements. The 18% reduction in VAT is clinically meaningful for metabolic health.

Cognitive function: the STAY trial

The STAY trial (Somatotropin, Aging, and Cognition; n=137, randomized, double-blind) evaluated tesamorelin in cognitively normal older adults aged 55-87 years over 20 weeks:

• Executive function improved in the tesamorelin group
• Verbal memory improved in a subset analysis
• Brain amyloid-beta burden decreased (measured by PET imaging)
• BDNF (brain-derived neurotrophic factor) levels increased

(Baker et al., 2012)

These findings are preliminary. A single trial with a modest sample size and relatively short duration. However, the reduction in brain amyloid-beta is particularly notable, as amyloid accumulation is a hallmark of Alzheimer’s disease pathology. The implications extend beyond tesamorelin to the broader question of whether GH/IGF-1 pathway stimulation supports cognitive health during aging, relevant to all GHRH analogs and GH secretagogues.

Further research is needed before cognitive benefit can be considered established.

Liver fat reduction (NAFLD)

Tesamorelin has also shown efficacy for reducing hepatic (liver) fat in HIV-positive patients with non-alcoholic fatty liver disease. In a clinical trial, tesamorelin reduced liver fat fraction by approximately 37% compared to placebo, with improvement in hepatic fibrosis biomarkers (Stanley et al., 2014).

Liver fat reduction is a growing area of interest, as NAFLD is increasingly recognized as a major contributor to metabolic disease. Whether tesamorelin’s liver fat effects extend beyond the HIV population is plausible but not yet confirmed in dedicated trials.

What Tesamorelin Has Been Demonstrated to Do (Summary)

Based on clinical evidence:

• Visceral fat reduction: ~18% decrease measured by CT scan (Phase III data)
• GH/IGF-1 normalization: restoration of age-appropriate levels
• Modest lipid improvement: triglycerides and cholesterol
• Liver fat reduction: significant in NAFLD studies (HIV population)
• Lean mass preservation: slight increase observed
• Cognitive function improvement: preliminary evidence from one trial
• Brain amyloid reduction: preliminary PET imaging data

How Tesamorelin Compares to Other GHRH Analogs

Understanding where tesamorelin fits in the GHRH analog landscape:

Tesamorelin vs. sermorelin: Sermorelin has a former FDA approval (diagnostic) and the longest clinical safety record. Tesamorelin has the current FDA approval and stronger Phase III body composition data. Sermorelin has a shorter half-life (~10-20 min vs. ~26 min). Both require daily injection.

Tesamorelin vs. CJC-1295 (no DAC): CJC-1295 has comparable enzymatic stability (~30 min half-life) but no FDA approval and minimal clinical fat loss data. Tesamorelin’s visceral fat evidence is substantially stronger. CJC-1295 is available as a research chemical at lower cost.

Tesamorelin vs. CJC-1295 (with DAC): The DAC version offers weekly dosing convenience (6-8 day half-life) but creates sustained rather than pulsatile GH elevation. Tesamorelin’s daily injection produces more physiological GH dynamics. CJC-1295 with DAC has Phase I/II data but nothing comparable to tesamorelin’s Phase III program.

Tesamorelin vs. ipamorelin: These work through different receptor systems (GHRH-R vs. GHS-R1a). They are complementary rather than interchangeable. Combining a GHRH analog with a ghrelin mimetic is the basis for many community-reported GH protocols. See our muscle growth guide.

Tesamorelin vs. semaglutide: Different mechanisms entirely. Semaglutide works through GLP-1-mediated appetite suppression and metabolic effects. Tesamorelin works through GH-mediated lipolysis. Semaglutide produces greater total weight loss; tesamorelin is more specifically targeted at visceral fat. See our fat loss guide for a broader comparison.

Dosing

FDA-approved dosing (Egrifta SV)

• Dose: 2 mg subcutaneous injection, once daily
• Timing: fasted (consistent with other GHRH analogs)
• Injection site: abdomen (recommended in prescribing information), with rotation
• Duration: ongoing, with periodic reassessment of benefit

Off-label use patterns

In anti-aging clinical settings, tesamorelin is sometimes prescribed similarly to the approved protocol:

• Dose: 1–2 mg subcutaneously, daily
• Timing: before bed or morning fasted
• Some physicians describe cycling protocols (e.g., 6 months on, 2 months off), though the FDA-approved use is continuous

Reconstitution (for non-branded sources)

Compounded or research-grade tesamorelin is reconstituted with bacteriostatic water, refrigerated after reconstitution, and injected subcutaneously.

Side Effects and Safety

Tesamorelin’s safety profile is well-characterized from Phase III clinical trial data, a significant advantage over most peptides in this space.

Common side effects (from Phase III data)

• Injection site reactions: erythema, pruritus, pain, swelling (most common, ~24%)
• Arthralgia (joint pain): 13% (a recognized GH class effect)
• Myalgia (muscle pain): 5%
• Peripheral edema: 6% (water retention, GH class effect)
• Paresthesia (tingling): carpal tunnel-like, GH class effect

Important safety considerations

Glucose metabolism. Like all GH-elevating compounds, tesamorelin can reduce insulin sensitivity. In clinical trials, the effect was modest and manageable. Fasting glucose and HbA1c should be monitored, particularly in individuals with pre-existing insulin resistance or diabetes risk.

IGF-1 elevation. Treatment normalizes IGF-1 in most patients, but monitoring is recommended to avoid supraphysiological levels. Chronically elevated IGF-1 has theoretical implications for cancer risk, though this relationship is complex.

Fluid retention. GH class effect. Significant in some patients and worth monitoring, particularly for blood pressure effects.

Monitoring recommendations

Given the FDA-approved status, established monitoring guidelines exist:

• IGF-1 levels at baseline and periodically during treatment
• Fasting glucose and HbA1c
• Clinical assessment of fluid retention and joint symptoms
• Periodic reassessment of treatment benefit vs. risk

Legal Status

United States

FDA-approved as Egrifta SV for HIV-associated lipodystrophy. Available by prescription. Off-label use for anti-aging and body composition is legal with a prescription, though insurance coverage is typically limited to the approved indication. Also available through compounding pharmacies and as a research chemical.

WADA

Prohibited. GHRH and its analogs are banned under Section S2 in and out of competition.

Frequently Asked Questions

Is tesamorelin the best GHRH analog for fat loss?

Tesamorelin has the strongest clinical evidence for visceral fat reduction among GHRH analogs, with Phase III data and CT-measured outcomes. CJC-1295 probably produces similar GH elevation but lacks comparable fat loss data. Sermorelin has a stronger long-term safety record but weaker body composition evidence. If clinical evidence quality is the priority, tesamorelin has the best case among GHRH analogs specifically. For overall fat loss, semaglutide and tirzepatide produce larger total weight reductions through different mechanisms.

Can a doctor prescribe tesamorelin for general fat loss (not HIV-related)?

The FDA-approved indication is HIV-associated lipodystrophy. Off-label prescription is at the physician’s discretion. Some anti-aging and functional medicine practitioners prescribe tesamorelin for age-related visceral adiposity. Insurance coverage for off-label use is typically limited.

Does tesamorelin affect insulin sensitivity?

Like all GH-elevating compounds, tesamorelin can reduce insulin sensitivity. In clinical trials, this effect was modest and did not result in clinically significant glucose elevations in most patients. However, monitoring is important, particularly for individuals with pre-existing insulin resistance, prediabetes, or type 2 diabetes.

What about the cognitive findings — are they reliable?

The STAY trial results are intriguing but preliminary. One trial with 137 participants over 20 weeks does not establish cognitive benefit. The brain amyloid PET imaging findings are particularly interesting from a mechanistic standpoint, but replication in larger, longer studies is needed. These findings should be viewed as generating hypotheses, not confirming clinical benefit.

How does tesamorelin compare to MK-677 for fat loss?

MK-677 is an oral ghrelin mimetic, a different class of compound that works on the GHS-R1a receptor rather than the GHRH receptor. MK-677 is convenient (oral, once daily) but lacks the Phase III fat loss data that tesamorelin has. MK-677 is also associated with more appetite stimulation, which can be counterproductive for fat loss goals. Tesamorelin’s clinical evidence for visceral fat reduction is substantially stronger.

Does tesamorelin need to be cycled?

The FDA-approved protocol is continuous daily use with periodic reassessment. In off-label settings, some practitioners describe cycling protocols, but this is based on clinical judgment rather than trial data. The theoretical rationale for cycling relates to potential pituitary desensitization, though clinical evidence for this with tesamorelin is limited.

References

1. Falutz J, et al. “Metabolic effects of a growth hormone-releasing factor in patients with HIV.” N Engl J Med. 2007;357(23):2359-70. PubMed
2. Baker LD, et al. “Effects of Growth Hormone–Releasing Hormone on Cognitive Function in Adults With Mild Cognitive Impairment and Healthy Older Adults.” Arch Neurol. 2012;69(11):1420-9. PubMed
3. Stanley TL, et al. “Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation.” JAMA. 2014;312(4):380-9. PubMed
4. Dhillon S. “Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy.” Drugs. 2011;71(8):1071-91. [research needed]
5. Falutz J, et al. “A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation.” AIDS. 2005;19(12):1279-87. [research needed]

Related Articles

Peptide

AOD-9604: Research, Mechanism, and What the Evidence Actually Shows

An evidence-first look at AOD-9604 — the GH fragment studied for fat loss. Clinical trial results, mechanism of action, safety data, and an honest assessment of efficacy.

Peptide

CJC-1295: What the Evidence Says About This GHRH Analog

An evidence-first review of CJC-1295, covering how it differs from native GHRH, DAC vs no-DAC variants, clinical trial data, and what the research shows about GH stimulation.

Peptide

Ipamorelin: What the Evidence Says About This Selective GH Secretagogue

An evidence-first review of ipamorelin, covering its selectivity compared to other GHRPs, what clinical and preclinical research has demonstrated, and what remains unknown.